Sat. Mar 25th, 2023

The application delivers information recording, with customisable fields for ADE’s, study topic demographics, and illness information. Credit: National Cancer Institute on Unsplash.

BioVaxys Technologies has acquired clinical research management business TAETSoftware (TAETCo), which develops and commercialises the Trial Adverse Events Tracker (TAET) technologies platform.

TAET is a computer software application that permits clinical study subjects to record and submit clinical trial Adverse Drug Events (ADE) reports to the trial sponsors in true time. 

It has been developed to increase the tracking of adverse events and/or side effects in participants enrolled in clinical trials.

The application delivers study participants with a safe and private hyperlink to quickly update the investigators about any adverse events they are experiencing.

The particulars can be updated onto an on line database for true-time assessment by trial investigators.

TAET delivers a higher degree of information recording, with customisable fields for ADE’s, study topic demographics, and illness information, as nicely as other study-associated variables.

This delivers the capability for study participants and investigators to direct message every single other if necessary.

BioVaxys Technologies CEO James Passin stated: “The acquisition of TAETCo delivers BioVaxys with a third, low-danger, close to-term income creating item, supporting our core small business in cancer and viral vaccine improvement. 

“In addition to delivering a charge-primarily based item for recording clinical study ADE’s for CROs and study sponsors, BioVaxys will seek to leverage current breakthroughs in artificial intelligence by collaborating with one particular or far more players in healthcare information mining to create insights into correlations amongst demographics and other variables and ADEs.”

Below the terms of the deal, the business issued 24.five million popular shares to TAETCo shareholders, along with two.five million added popular shares that will be payable immediately after testing the beta version of the application.

BioVaxys Technologies plans to discover the prospective of supplying blinded demographic and illness information to organizations with an interest in healthcare analytics and information mining.

By Editor

Leave a Reply